Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion type Assertion NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_head.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion description "[Since Cot represents an alternative mode, independently of RAF, to activate Erk1/2, all these data strongly suggest that molecular targeting of Cot may be a potential new specific strategy for ALCL lymphomas therapy, without the fully disturbance of the Erk1/2 function.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_provenance.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion evidence source_evidence_literature NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_provenance.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion SIO_000772 21741362 NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_provenance.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion wasDerivedFrom befree-20140225 NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_provenance.
- NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_assertion wasGeneratedBy ECO_0000203 NP660013.RAGJSXPBq0F2o-J2UqPdJWmuLgd7mFealoTpErW0jlAvc130_provenance.